Member Info for VistaMan

Why can't every shareholder on this board see that Sanderson is taking you all for a ride with his ridiculous salary in relation to the £27MM market cap and of course his ZERO shareholding? That on top of incredible value destruction for shareholders, in my case 94%! To give you a comparison Andrew Austin of Kistos takes a £30k salary in a £149 MM market cap company. To ensure alignment with shareholders he owns 17% of the shares of the company through his own money, not gifts and has a track record of value creation for shareholders, eg a 42X rise in value of RRE from launch to sale. There were a few of the resident rampers on here were stupid enough to state UKOG was a better bet than RRE when I brought it up as one of a number of benchmarks on here a year ago. I certainly will not be pouring any good money after bad whilst Sanderson is still in charge!

Regarding 15% US witholding tax, if you hold your shares in a SIPP and have a completed W8-BEN on file there is NO witholding tax as there is a US/UK tax treaty. My account is with HL. I have lost track the number of times this question has come up on this BB.

Keri, the market cap is already silly high at £43MM. Take I3E as a calibration, its market cap is £68MM and produces >9000 boepd and is paying a dividend. Throw into the mix that a massive dilutive bucket shop placing is coming to pay for their Turkish adventures and there is only one sensible thing to do and you might need to be very quick!

I agree with what the good Doc said about the use of a pencil, calculator, etc. (& spreadsheet) I sold out of I3 in November 19 at a significant loss and not too enamered with the BOD. I started purchasing I3 again in August 2020 after publication of the admission document. By going through this in some detail and taking account of the macro view on oil price it was enough for me to consider I3 as a relatively high reward low risk investment. I have purchased an additional 6 lots since and am now in profit multiple times what I lost in 2019. Lets hope we get the dividend we all hope for in the next few weeks and thanks again Doc for the research freely shared.

RIc, if you don't have any shares you won't have any open offer entitlement!

Its still a much cheaper alternative for the UK even if 10% of the population received it!

Hunter, thank you, I'll check with my broker tomorrow also.
Vista

Hello, I have been holding Ferrexpo shares since early April and didn't notice until today that a 35% witholding tax has been applied to my dividends. Has anyone been successful in reclaiming the 20% under the double taxation treaty between UK and Switzerland? Does your broker do it or do you have to do it individually? Does it matter if they are held in an ISA or SIPP?
Thanks.

winwin, I am certainly not denying the importance of a vaccine but even Pfizer quote 90% and its unlikely to be as high as that in some of the more at risk categories. That still leaves a lot of people open to infection given vaccination rates and immunity duration uncertainities. Surely you can see the attractiveness of an effective therapeutic for COVID?

Eva, Could I ask relatively to other COVID therapeutic companies, have they struggled to react quickly enough? Remember getting a diagnostic test approved is somewhat less challenging than a therapeutic approval. I think once SNG realised that despite their positive Phase II data that there was not going to be any shortcuts they have geared up for Phase III quite well. All that is currently approved is Dexamethasone which is only partially efective and Rendesivir which appears to offer little effectiveness relative to morbidity.

BOJO,
I think you missed IMHO in your diatribe against SNG, AVCT, ODX and GDR. Your moniker is well chosen for verbosity. Not one of them is a straight COVID play. SNG stands alone with a therapeutic to treat COVID (and COPD) patients and there will continue to be COVID patients post vaccines. ODX has multiple strings to its bow and not just COVID antigen/antibody tests. GDR has products very similar to NCYT once it gets regulatory approval and yes tests will be required for years to come. As for AVACTA, whilst in the short term it became a COVID testing play its real value belongs in its AFFIRMER / pre-CISION technology in therapeutics and we won't have to wait much longer to see the outcomes.
GLA

First post on this board I believe. My first of my purchases was at 61p and have made many since. The potential of the therapeutic drugs and drug delivery systems which are all patented are massive. The presentation of Stemprinter at ASCO was the moment my investment was derisked. I continued to purchase including my last at 191p after the placing. The company is fully cashed for the next few years so no dilutive placings to destroy shareholder value. The last placing was an excellent move by the BOD, the spike in the upper 200s in my opinion was caused by US investor confusion between 2X and 5X ADSs so I am not concerned by the current SP. The delay in the announcement of the demerger details / record date is likely to be because a bid has been received (for STEM) and negotiations are active, all in my opinion but it certainly doesn't take that long to establish a tax position. What might STEM be worth on a sale? I can't believe they would let it go for less than $1 bn given an inferior competitor went for $2.8bn. That would be a very nice dividend across the 191 million shares in issue!

Bradley, Where did you get the average P/E ratio of 19.2 from. In my experience oil producers are nowhere near this and that is what UOG are, not a wild catter.

YES

Jolly, yes he did, he just stated he has sold on friday.

NK, I think you are out by a factor of a 1,000

Ghia, How often do Morningstar update this? I thought it was monthly? If so why did it not show Acacia in the list of IIs?

Troll, usual ramptastic, deliberately non-factual nonsense, not a good sign for HH! Where on earth will the money come from? There will be even more significant dilution and anyone buying now doesn't understand they will get an opportunity much lower.

Troll, more baseless ramoing, the HH-1 well at 300 BPD flow does not justify the current SP, in fact it justifies about 0.06p when using traditional oiler valuation metrics. So you see some upside is already priced in. You never use numbers to justify your position, I can only assume you don't have any.

Troll, you really do try and mislead people. Its not $30 profit, OPEX MIGHT be now $13 / barrel but their total cost is still well north of $20 per barrel. Remember Sanderson's cut alone works out at $8.75 for everyone of those 300 bpd. Truth doesn't suit your purpose however!